Mirae Asset Global Investments
ITOS

Mirae Asset Global Investments’s iTeos Therapeutics ITOS Stock Holding History

Mirae Asset Global Investments’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,479
Closed -$14.7K – 1674
2025
Q2 		$14.7K Buy
1,479
+257
+21% +$2.07K ﹤0.01% 1439
2025
Q1 		$7.72K Buy
1,222
+5
+0.4% +$37 ﹤0.01% 1494
2024
Q4 		$8.91K Sell
1,217
-104
-8% -$894 ﹤0.01% 1527
2024
Q3 		$13.9K Buy
1,321
+208
+19% +$3.17K ﹤0.01% 1478
2024
Q2 		$17.3K Sell
1,113
-10,185
-90% -$146K ﹤0.01% 1402
2024
Q1 		$157K Buy
11,298
+169
+2% +$1.84K ﹤0.01% 2306
2023
Q4 		$122K Sell
11,129
-2,685
-19% -$26.6K ﹤0.01% 2428
2023
Q3 		$151K Sell
13,814
-190
-1% -$2.43K ﹤0.01% 2374
2023
Q2 		$186K Sell
14,004
-1,433
-9% -$20.4K ﹤0.01% 2369
2023
Q1 		$210K Buy
15,437
+4,301
+39% +$77.1K ﹤0.01% 2309
2022
Q4 		$217K Buy
11,136
+12
+0.1% +$234 ﹤0.01% 2272
2022
Q3 		$212K Buy
+11,124
New +$256K ﹤0.01% 2321

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mirae Asset Global Investments's ITOS Position: Q3 2025 in Review

Mirae Asset Global Investments sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 1,479 shares — an estimated $14.7K sold.

Mirae Asset Global Investments first reported a position in ITOS in Q3 2022 and held it in 12 quarters. The position peaked at $217K in Q4 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • Mirae Asset Global Investments reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mirae Asset Global Investments sold 1,479 iTeos Therapeutics shares in Q3 2025, an estimated $14.7K.
  • Mirae Asset Global Investments first reported a position in iTeos Therapeutics in Q3 2022 and held it in 12 quarters.
  • Mirae Asset Global Investments's iTeos Therapeutics position peaked at $217K in Q4 2022.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Mirae Asset Global Investments's 13F filing for Q3 2025, filed 3 Nov 2025.